<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="279">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832932</url>
  </required_header>
  <id_info>
    <org_study_id>20210103MEBO</org_study_id>
    <nct_id>NCT04832932</nct_id>
  </id_info>
  <brief_title>The COVID-19 Back-to-Normal Study</brief_title>
  <official_title>A Phenotypic Study of Safety, Tolerability, Reactogenicity, Immunogenicity, and Virus Shedding Potential of Emergency-Use-Authorized Vaccines Against COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mebo Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aurametrix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mebo Research, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      During the study, members of different neighborhood and digital communities will be followed&#xD;
      post COVID-19 vaccination.&#xD;
&#xD;
      Injection-site (local) and systemic reaction data will be assessed on vaccination day and&#xD;
      afterwards using either web surveys or personal communication, depending on study participant&#xD;
      preference.&#xD;
&#xD;
      Hypothesis to be tested The safety profile and the magnitude and durability of immune&#xD;
      responses to the COVID-19 vaccines as well as adverse reactions depend on health conditions,&#xD;
      metabolism and microbiomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a&#xD;
      Public Health Emergency of International Concern in January 2020 and upgraded to pandemic in&#xD;
      March 2020. First vaccines to prevent COVID-19 were authorized for emergency use in the US in&#xD;
      December 2020, but a number of unknowns still remains. One of these unknowns is the&#xD;
      relationship of the microbiota, gut dysbiosis and impaired metabolism with active immunity to&#xD;
      pathogens and vaccines and tolerance to antigens. Study groups will be based on age,&#xD;
      metabolism and self-reported symptoms. Data will be collected continuously via surveys and&#xD;
      investigator-participant interactions, as needed. Statistical methods used will be the ones&#xD;
      with the greatest power.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse reactions/events</measure>
    <time_frame>10 days post-doses 1 and 2</time_frame>
    <description>Percentage of occurrence, types, duration and severity of adverse events occurring within 10 days post-doses 1 and 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term adverse events</measure>
    <time_frame>Throughout the study period, until 12 months post-final-dose</time_frame>
    <description>Percentage of occurrence, types, duration and severity of adverse events throughout study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with COVID-19 Disease</measure>
    <time_frame>From 14 days after completion of the 2-dose regimen up to 12 months post-final-dose</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>COVID-19 Vaccines</condition>
  <arm_group>
    <arm_group_label>75 years of age or older</arm_group_label>
    <description>individuals 75 years of age and older who received COVID-19 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>65-74 years of age</arm_group_label>
    <description>individuals 65-74 years of age who received COVID-19 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16-64 years of age</arm_group_label>
    <description>Individuals in 16-64 age range who received COVID-19 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEBO/PATM</arm_group_label>
    <description>Individuals in 16-69 age range with present or past MEBO/PATM symptoms who received COVID-19 vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 vaccine</intervention_name>
    <description>Emergency-use authorized COVID-19 vaccine</description>
    <arm_group_label>16-64 years of age</arm_group_label>
    <arm_group_label>65-74 years of age</arm_group_label>
    <arm_group_label>75 years of age or older</arm_group_label>
    <arm_group_label>MEBO/PATM</arm_group_label>
    <other_name>BNT162b2</other_name>
    <other_name>mRNA-1273</other_name>
    <other_name>JNJ-78436735</other_name>
    <other_name>AZD1222</other_name>
    <other_name>Gam-KOVID-Vak</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals 16 or older interested in vaccinating&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals 16 or older at the time of consent&#xD;
&#xD;
          -  Intention to vaccinate and of being available for entire study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any illness or condition that in the opinion of the investigator may affect the safety&#xD;
             of the participant or the evaluation of any study endpoint.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Gabashvili, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mebo Research, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria de la Torre</last_name>
    <phone>(786) 228-6880</phone>
    <email>maria.delatorre@meboresearch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>MEBO Research, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria de la Torre</last_name>
      <phone>786-228-6880</phone>
      <email>maria.delatorre@meboresearch.org</email>
    </contact>
    <contact_backup>
      <last_name>Michael Arenibar, MBA</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kahite</name>
      <address>
        <city>Vonore</city>
        <state>Tennessee</state>
        <zip>37885</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Irene G Allsup, PhD</last_name>
      <phone>408-341-9355</phone>
      <email>studies@aurametrix.com</email>
    </contact>
    <contact_backup>
      <last_name>Lavonne Mitchell</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mary Washington Hospital Research</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine Emery, BSN, RN</last_name>
      <phone>540-741-4708</phone>
      <email>Christine.Emery@mwhc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mebo Research (Uk)</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W10 5LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Cole Flaherty</last_name>
      <email>cole@meboresearch.co.uk</email>
    </contact>
    <contact_backup>
      <last_name>Maria de la Torre</last_name>
      <email>maria.delatorre@meboresearch.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-Related Side Effects and Adverse Reactions</keyword>
  <keyword>Long-term adverse effects</keyword>
  <keyword>Immunogenicity, Vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>individual participant data will remain confidential, unless specifically requested to be shared by the participant</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

